In this study, the results of the integrated bioinformatical analysis suggested FGFR3 as a possible indicator for TME status remodeling and clinical outcomes such as distant metastasis, overall survival rate, and immunotherapy response to bladder cancer. Here, FGFR3 is linked to urinary bladder cancer.